Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Interview with Greg Landrum at Elsevier: What are the ingredients of a successful Open Source cheminformatics software?
Posted on November 30th, 2020 by Elena HerzogChemistry
(Written by Elena Herzog in collaboration with Markus Fischer, Gerd Blanke, Jarek Tomczac and Gabrielle Whittick)
RDKit, a collection of cheminformatics and machine learning software, is assisting in solving chemical information challenges. The founder and creator of RDKit, Greg Landrum, was interviewed by the UDM (Unified Data Model) team, facilitated by Elsevier, to share his experience on what the road to success looks like and what ingredients does an open source project need to have to be successful. The learnings from the interview would help to shape the future of the UDM project, which is transferring from its consortium-led Pistoia Alliance model to a community-led model.(more…)
Posted on November 18th, 2020 by Ani MarrsChemistry
Synthetic chemistry has been with us for centuries, but it is now entering a new frontier. Big data, AI and machine learning are unlocking a predictive power that is transforming the conceptualization and optimization of synthetic routes.(more…)
Posted on November 16th, 2020 by Xuanyan XuChemistry
The International Life Sciences Awards, an initiative from Global Health & Pharma Magazine (GHP) that is now in its fifth year, recognizes industry innovators – and this year that has included honoring Reaxys as an innovation leader by awarding it the Best Chemistry Predictive Analytics Specialists 2020 for its best-in-class Predictive Retrosynthesis software.(more…)
Posted on November 16th, 2020 by Xuanyan XuCOVID-19
Wasting no time to start enacting his forthcoming administration’s plan for tackling COVID-19, new president-elect of the United States, Joe Biden, has unveiled his coronavirus advisory team. “Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts,” he stated.(more…)
Posted on October 23rd, 2020 by Ani MarrsCOVID-19
A renewed interest in whether the BCG vaccine (for tuberculosis) could also have an application for COVID-19 has been on the rise, as evidenced by this recent Cell publication, the University of Exeter’s involvement in the BRACE Trial and ongoing general press coverage. Furthermore, the list of clinical trials focusing on this area is continuing to grow (and is available here).(more…)
Posted on October 14th, 2020 by Xuanyan XuPharma R&D
Chemotherapy has been a powerful method for fighting cancer for decades. One of the most effective therapies available, it is also known for weakening the patient and causing harsh side effects like pain, nausea, and hair loss. This is because in its zeal to attack cancer cells, chemo also kills healthy cells.(more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.